When you look at ROW, It's very early days.
Our first true ROW drug - I'll take it.
The structure will eventually pay off in spades - IMO.
"With our 2022 revenue estimates currently forecasting approximately $288.6 million, the addition of Exelon represents a fully integrated revenue accretion of 27 per cent,” Novak wrote." So, we still have a hundred million in the bank and that will likely have to do us for now.
Remember ... there's still $40M outstanding with CRA/QRA and that could go either way. Would love to put that cash back in the bank.
Eventually the fund investments slowly trickle back too.
So ... the creation of a well oiled machine where cashflow is self-funding growth initiatives doesn't seem all that far away. Also, we have the ongoing pursuit of small pharma partners to create the mega licensing deals of the future - but that will be more defined say 10-15 years from now.
Then ... we still have the shelf prospectus as a back-up for some big "gotta have" opportunities (maybe in Mexico). Surely, Goodman could also utilize debt in the short-term and convert the debt in a future prospectus at a better share price. There are options (IMO).
https://www.cantechletter.com/2021/04/gud-times-knight-therapeutics-wins-target-raise-at-raymond-james/